| 组织蛋白酶D新的糖基化异构体在肺癌中表达的临床意义及其与预后的相关性 |
| |
| 引用本文： | 张慧娟,郑晓伟,乔玲,李鸿超,常文静,卢锋,贾彩云. 组织蛋白酶D新的糖基化异构体在肺癌中表达的临床意义及其与预后的相关性[J]. 解剖学报, 2018, 49(2): 191-197. DOI: 10.16098/j.issn.0529-1356.2018.02.009 |
| |
| 作者姓名： | 张慧娟 郑晓伟 乔玲 李鸿超 常文静 卢锋 贾彩云 |
| |
| 作者单位： | 1.河南大学抗体药物开发技术国家地方联合工程实验室，河南开封 475004; 2.河南省濮阳市中医院检验科，河南 濮阳 475000; 3.河南省濮阳市油田总医院病理科，河南 濮阳 475000
|
| |
| 基金项目： | Cathepsin D新的糖基化异构体在肺癌发生发展中的作用及分子机制 |
| |
| 摘 要： | 目的 探讨组织蛋白酶D（CTSD）新的糖基化异构体与肺癌临床病理特征及预后的相关性。 方法 应用免疫组织化学和半定量RT PCR方法检测119例肺癌组织和39例癌旁组织中CTSD的表达；Western blotting分析CTSD各异构体表达特点；去糖基化实验检测CTSD 蛋白的糖基化修饰；Kaplan-Meier分析66kD异构体、临床病理资料与肺癌术后整体生存期的相关性。 结果 CTSD在肺鳞癌、腺癌和小细胞肺癌组织中高表达；66kD蛋白为CTSD新的糖基化异构体，该异构体表达与肺癌组织类型、临床分期、淋巴结转移和患者的吸烟史密切相关（P<0.05），阳性表达和阴性表达患者术后中位生存时间分别为20.0和30.0个月（P<0.05）；肺癌组织类型、临床分期、淋巴结转移、肿瘤大小和66kD异构体表达是影响肺癌预后的独立因素。 结论 CTSD 66kD异构体阳性表达可能是肺癌预后不良的分子标志物之一。
|
| 关 键 词： | 肺癌 组织蛋白酶D 糖基化异构体 免疫印迹法 人 |
| 收稿时间： | 2017-05-26 |
| 修稿时间： | 2017-11-29 |
Clinical significance and correlation with prognosis of novel glycosylation isoform of cathepsin D expression in lung cancer |
| |
| ZHANG Hui-juan ZHENG Xiao-wei QIAO Ling LI Hong-chao CHANG Wen-jing LU Feng JIA Cai-yun. Clinical significance and correlation with prognosis of novel glycosylation isoform of cathepsin D expression in lung cancer[J]. Acta Anatomica Sinica, 2018, 49(2): 191-197. DOI: 10.16098/j.issn.0529-1356.2018.02.009 |
| |
| Authors: | ZHANG Hui-juan ZHENG Xiao-wei QIAO Ling LI Hong-chao CHANG Wen-jing LU Feng JIA Cai-yun |
| |
| Affiliation: | 1.He’nan University Joint National Laboratory for Antibody Drug Engineering,He’nan Kaifeng 475004, China; 2.Department of Clinical Laboratory，Puyang Hospital of Traditional Chinese Medicine, He’nan Puyang 475000, China; 3.Department of Pathology, Puyang Oilfeld General Hospital, He’nan Puyang 475000, China |
| |
| Abstract: | Objective To study the correlation of novel glycosylation isoform of cathepsin D (CTSD) expression with clinical features and its prognostic value in lung cancer. Methods Immunohistochemistry and Semi-quantitative RT-PCR were used to examine the cathepsin D expression, and Western blotting to analyze characterization of cathepsin D isoforms expression in 119 lung cancer tissues and 39 paraneoplastic tissues. Deglycosylation experiment was performed to check glycosylation-modified condition of cathepsin D. The association of 66kD isoform expression with clinical features and lung cancer prognosis was determined by Kaplan-Meier survival analysis. Results Cathepsin D highly expressed in squamous carcinomas, adenocarcinoma and small cell carcinoma tissues. 66kD protein form of cathepsin D was a novel glycosylation isoform of cathepsin D, its expression was associated with lung cancer histological type, clinical stage, lymph node metastasis and smoking status(P<0.05). The median survival time of lung cancer with 66kD isoform positive and negative expression were 20.0 months and 30.0 months, respectively (P<0.05). Histological type, clinical stage, lymph node metastasis, tumor size and 66kD isoform were independent prognostic factor of lung cancer. Conclusion Positive expression of 66kD isoform of cathepsin D may be one of molecular markers which correlate with poor prognosis of lung cancer. |
| |
| Keywords: | Lung cancer Cathepsin D Glycosylation isoform Western blotting Human |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《解剖学报》浏览原始摘要信息 |
|
点击此处可从《解剖学报》下载全文 |
